Search

Cemiplimab

[L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).

Magnesium gluconate

Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids … It demonstrates the highest oral bioavailability of magnesium salts [L2608] and is used as a mineral supplement.

Miglustat

Miglustat was first developed as an anti-HIV agent in the 1990s.

Technetium Tc-99m pyrophosphate

A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in dif...

Spironolactone

It binds to mineralocorticoid receptors and functions as aldosterone antagonists.[A178192] It promotes sodium and water excretion and potassium retention.

Neratinib

Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.

Potassium acetate

Potassium sulfate

Ditiocarb zinc

Ditiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen.

Rozanolixizumab

Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.